abuse. Since 1980, there has been an increase in the numbers of deaths and hospitalizations attributed to PAH, particularly among women and older adults. Whether there is a true increase in the incidence of this disease, or whether this represents improved awareness and diagnosis is unknown. 4 What is known is that since 1995, there has been an explosion in new treatments for PAH that increase the quantity and quality of PAH patients' lives.
Pulmonary hypertension (PH) is a hemodynamic finding of elevated pulmonary artery pressure (PAP) higher than normal. The clinical definition of PAH is mean PAP higher than 25 mm Hg at rest, or higher than 30 mm Hg with exercise, with normal leftsided pressures represented by a pulmonary capillary wedge pressure (PCWP) of 15 mm Hg or lower. These hemodynamic findings are associated with a vasculopathy characterized by smooth muscle hypertrophy, intimal hyperplasia, and in situ thrombus formation. Right ventricular hypertrophy and dilatation occurs in response to the increased pulmonary vascular resistance (PVR). 2 PH has been classified into PAH, pulmonary venous hypertension, PH associated with hypoxemia, and PH due to chronic thrombotic 5 and/or embolic disease (Table 1) . 5 The focus of this discussion is PAH, also referred to as World Health Organization Group I Pulmonary Arterial Hypertension.
PAH is a progressive disease characterized by increasing PAPs, increasing PVR, and ultimately decreasing cardiac output. The vasculopathy is characterized by intimal, medial, and adventitial proliferation, and intimal atheromas or plexiform lesions. 6 Prognosis without treatment is grim, especially for patients with severe symptoms. Data from the NIH Registry (from the days before the availability of PAH treatment) showed a median survival of 2.8 years. 7 The prognosis for patients with scleroderma who develop PAH is also poor. In one series of patients with scleroderma, one-third developed PH, with a median survival of 12 months after the development of PH. 8 PAH is a diagnosis of exclusion. The hemodynamic finding of PH requires investigation into causes, systematically ruling out other, more common causes of PH. The symptoms of PAH are nonspecific and vague; in fact, in the early stages of the disease, there may be few if any symptoms. Patients and their physicians commonly attribute symptoms of fatigue, shortness of breath with activity and palpitations to stress, deconditioning, obesity, asthma, or anxiety. It is not uncommon for patients (particularly females) to be symptomatic for 2 to 3 years before the correct diagnosis is made. Often, the advent of right heart failure gets the healthcare provider's attention. In addition to the symptoms noted above, patients may experience chest pressure from right ventricular (RV) ischemia and dizziness, leading to syncope with activity. Right heart failure may present with peripheral edema, weight gain from fluid retention, ascites, and abdominal discomfort.
Particular attention must be paid to patients with these symptoms in groups at risk of developing PAH. These groups include persons with a known genetic mutation associated with PAH or a first-degree relative with IPAH, congenital heart disease, or systemic-to-pulmonary shunts, systemic sclerosis, HIV positive or portal hypertension undergoing evaluation for liver transplant. 9, 10 The incidence of PAH in systemic sclerosis has been reported in various series as 9% to 33%. 7, [11] [12] [13] The incidence of PAH in HIV is 1 in 200, 14, 15 and approximately 5% to 10% of patients being evaluated for liver transplant present with portopulmonary hypertension. 16 In these groups at risk, periodic screening for symptoms and screening tests are warranted.
When taking the history, patients with symptoms should be questioned about family history of cardiopulmonary problems, particularly female relatives who died young with cardiopulmonary symptoms. Patients should be questioned about drug use, including anorexigens such as fenfluraminephentermine (fen-phen), amphetamines, methamphetamine, and cocaine. To assess functional status, patients should be questioned about symptoms during activities of daily living and physical activity. The NYHA Classification for heart failure symptoms was modified for PAH patients at the World Symposium for Pulmonary Hypertension in 1998 ( Table 2 ). 17 Functional status should be assessed at the initial consultation and at each subsequent visit.
On physical examination, the PAH patient often has an RV lift, increased P 2 component of the second heart sound, and murmurs of tricuspid regurgitation and pulmonic insufficiency. Signs of right heart failure include hepatomegaly, peripheral edema, jugular venous distention, ascites, and a right-sided S 3 and/or S 4 . 2, 9 The best screening test for suspected PAH is the transthoracic echocardiogram. The right ventricular systolic pressure (RVSP), right chamber dimensions and an evaluation of RV function, left-sided contractility, and valve function can be obtained. A contrast echo can be done to evaluate for intracardiac shunts. 9 If findings on the history, physical examination, or screening tests lead to suspicion of PAH, additional tests are performed to clarify and classify the diagnosis (Table 3) . These tests will rule out other causes of PH, identify etiologies of PAH, and provide information regarding prognosis and functional status. Right heart catheterization (RHC) remains the criterion standard to confirm the diagnosis of PAH. 9 During the RHC, pulmonary pressures (PA systolic and diastolic, mean PAP, PCWP, RVP, right atrial pressure [RAP]), cardiac output, and mixed venous oxygen saturation are measured. From these data, the PVR is calculated. If intracardiac shunting is suspected, oxygen saturations are obtained from superior vena cava, inferior vena cava, right atrium, right ventricle, pulmonary artery, and femoral artery. 24 Vasoreactivity testing with inhaled nitric oxide (NO), intravenous epoprostenol, or adenosine is performed to identify vasoreactive "responders." 9, 24 Patients who exhibited vasoreactivity and could be treated with high-dose calcium channel blockers (CCBs) had significantly better prognosis than nonresponders. 25 Vasoreactivity testing should only be done in patients without right heart failure and mild-moderate symptoms (not class III or IV). The agent used is titrated up until the patient becomes hypotensive (systolic blood pressure decrease of 10% or to 85 mm Hg or heart rate increase by 40% or >100 or <65 beats/min), has headache, nausea, or lightheadedness as the side effects, and the maximum dose is reached or the targets have been reached. Positive vasoreactivity is defined as a decrease in mean PAP of at least 10 mm Hg with a resulting mean PAP of less than 40 mm Hg with a normal or high cardiac output. 26 Once vasoreactivity is demonstrated, the patient should have a monitored trial of high-dose CCBs. Because of their negative inotropic effect, CCBs can precipitate right heart failure. Patients with suspected or documented PAH should never be empirically started on CCBs. Patients who do not tolerate CCBs are candidates for other PAH therapies. Only a fortunate 10% or less of patients with PAH are vasoreactive and can tolerate CCB therapy. 26 Once the diagnosis of PAH is confirmed, an assessment of the patient's risk can be made from the gathered data. Poor prognostic indicators 1,9 include high PAP, high RAP, low cardiac output, high (poor) functional class, presence of pericardial effusion, large right atrial size on echo, 27 and 6-minute walk test of less than 332 m. 28 A number of neurohormones are involved in the pathology of PAH. These mechanisms result in an imbalance between vasodilation and vasoconstriction with cell proliferation. The 3 main neurohormonal mechanisms that serve as therapeutic targets are the endothelin (ET-1), NO, and prostacyclin pathways (Fig 1) . 29 Endothelin has potent vasoconstrictor effects and induces cell proliferation in vascular smooth muscle. It promotes fibrosis and inflammation. Endothelin acts on 2 receptors, ET A and ET B . ET A receptors are located on pulmonary vascular smooth muscle cells, and their activation causes potent vasoconstriction by increasing the concentration of intracellular calcium. ET B receptors are located on pulmonary vascular endothelial cells and smooth muscle cells. When activated, they cause vasodilation via increased production of prostacyclin and NO in normal pulmonary vasculature. ET B receptors are also involved in clearance of ET-1. 29, 30 Overexpression of endothelin has been documented in chronic hypoxic PH, 31 IPAH, 30 systemic sclerosis, and fibrotic lung disease. 30, 32, 33 Treatment for PAH is aimed at blocking endothelin activity through blockade of both ET A and ET B receptors or selective blockade of ET A receptors.
NO is a potent vasodilator produced in the lung vascular endothelium by NO synthase from L-arginine. It relaxes vascular smooth muscle by increasing the production of cyclic guanosine monophosphate. 29 There is decreased endothelial NO synthase expression in PAH. 2 Phosphodiesterase type-5 (PDE-5) is the major enzyme responsible for the degradation of cyclic guanosine monophosphate and is abundant in the lung. Inhalation of NO, or inhibition of PDE-5, causes pulmonary vasodilation. 29, 34 Prostacyclin is produced by the vascular endothelium from arachidonic acid. It has vasodilator, antiproliferative, and antiplatelet properties. Low levels of prostacyclin and decreased expression of prostacyclin synthase have been found in PAH. 2 Administration of prostanoid analogs produces similar effects as endogenous prostacyclin. 35 Other mechanisms are under study for possible treatment strategies. Mutations in the bone morphogenetic protein receptor 2 (BMPR2) gene have been identified and associated with familial PAH. 36 Mutation in ALK1 has also been found in PAH. ALK1 and BMPR2 are receptors in the transforming growth factor β superfamily, which suppress cell proliferation and activate apoptosis. Statins (HMG-CoA reductase inhibitors) have antiproliferative and antiinflammatory effects and augment NO production. Elastase inhibitors, serotonin reuptake inhibitors, L-arginine supplements, antiplatelet agents, antiproliferative agents, and vasoactive intestinal peptide are all under study. 37 Treatment strategies for PAH include conventional/adjunctive therapy, FDA-approved therapies, and investigational/off-label therapies ( Table 4 ). The treatment goals in PAH include (1) increasing functional status, measured by 6-minute walk goal of more than 400 to 450 m, (2) improving functional class, measured by a goal of functional class II, (3) improving RV function, measured by normal RAP and reduction in RV dilatation, (4) improving quality of life by patient report, and (5) improving survival.
Conventional therapy is an adjunct to therapies aimed specifically at PAH. These therapies improve symptoms and quality of life, but do not treat PAH directly. Physical activity is important for maintaining muscle mass and feeling of well-being. Cardiopulmonary rehabilitation allows patients with PAH to exercise safely in a monitored setting, and is especially recommended for improving physical condition prior to lung transplantation. RV overload and right heart failure is treated with diuretics and sodium and fluid restrictions. Multiple diuretics with supplemental potassium are usually required. Supplemental oxygen as needed to keep oxygen saturation more than 90% at rest and during activity is recommended. 38 Anticoagulation with warfarin (goal INR 1.5-2.5) has been shown to increase survival. 25 Digoxin is used for its positive inotropic effect to support the right ventricle and may counteract neurohormonal activation that occurs in heart failure. 2 As previously mentioned, CCBs are only indicated for vasoreactive patients who present without right heart failure. Initiation of CCBs in vasoreactive patients must be closely monitored because many patients would not be able to tolerate their negative inotropic effect. 38 Treatment of PAH using the endothelin pathway involves endothelin receptor antagonists (ERAs). Bosentan (Tracleer) was the first oral medication for PAH, approved by the FDA in 2001. Bosentan blocks both ET A and ET B receptors, with slightly more affinity for ET A receptors. In animal models, bosentan caused pulmonary vasodilation, prevented vascular remodeling, and had positive effects on pulmonary fibrosis, vascular inflammation, and neurohormal activation. 39 In clinical trials, bosentan improved 6-minute walk distance and hemodynamics, 40 and these effects were maintained at 1 year. 41 The initial dose of 62.5 mg BID is titrated up to 125 mg BID after 1 month pending tolerance. Liver function tests (LFTs) must be monitored monthly for the duration of therapy. Elevation of liver enzymes more than 3 times normal occurred in 11% of clinical trial patients, and may preclude dose titration or remaining on the drug. In addition to LFT monitoring, women with childbearing potential must be tested monthly for pregnancy because of potential teratogenic effects. Serum hemoglobin should be monitored every 3 months for potential decrease. 42 The side effects of bosentan include headache, nasal stuffiness, flushing, fluid retention, and hypotension. Fluid retention may require uptitration of diuretics or preclude use of the drug. Drug interactions with cyclosporine and glyburide prohibit coadministration with these medications. 42 Two ET A selective endothelin blockers (sitaxsentan and ambrisentan) are in the drug pipeline. Sitaxsentan has a long duration of action, allowing for once daily dosing, and is 6000 times more selective for ET A than for ET B receptors. 38 Side effects are similar to bosentan, and LFT and hemoglobin monitoring are also required. 43 Sitaxsentan inhibits the CYP2C9 P450 enzyme, the principle enzyme for metabolism of warfarin, resulting in increased INR levels requiring reduction of warfarin dose. 38 Sitaxsentan (Thelin) has received an "approvable" letter from the FDA and is expected to be released soon. At this time, there is still limited data on whether selective ET A blockade is more beneficial than combined ET A and ET B blockade. The effect on liver enzymes appears to be a class effect of all ERAs, and most likely, all drugs in this class will require LFT monitoring. Drug interactions or incidence of certain side effects may be different between ERA medications that may make one preferable over another in specific patient groups.
The NO pathway may be manipulated either by administration of inhaled NO or blockade of PDE-5. Inhaled NO is FDA approved for use in pediatrics for PH; its use in adults is offlabel. At this time, NO is only available for hospitalized patients, and is used for vasoreactivity testing and to stabilize acutely ill or PAH patients undergoing surgery. Inhaled NO may be administered via nasal cannula up to 40 ppm, or via ventilator up to 80 ppm. Because it is delivered directly to the lungs, there are minimal systemic side effects. Sudden discontinuation of NO can cause rebound PH. Methemoglobin levels are monitored and kept under 5% of hemoglobin to avoid methemoglobin toxicity. 45 Monitoring of oxygen saturation is helpful in determining tolerance to weaning; invasive pulmonary arterial pressure monitoring may not be necessary in patients with known chronic PAH. Chronic, outpatient use of NO using conserving devices is under investigation.
Sildenafil is a PDE-5 inhibitor that increases cyclic guanosine monophosphate in the pulmonary vasculature and augments the vascular response to endogenous or inhaled NO, promoting pulmonary vasodilation. Sildenafil augments the vasodilation and chronic effects of prostacyclin. 38 In pulmonary fibrosis with PH, it is selective for well-ventilated lung areas, resulting in better gas exchange than for other vasodilators that increase shunting. Long-term beneficial effects have also been noted in nonoperable chronic thromboembolic pulmonary hypertension. 45 The addition of sildenafil to iloprost produced greater pulmonary vasodilation than either agent alone, and improved exercise capacity and hemodynamics when added to patients whose condition are deteriorating on iloprost. 29 Sildenafil reduced RV mass and improved 6-minute walk distance in a 16-week trial, thus comparing it to bosentan. There was no significant difference in the improvements between the two treatment groups. 34 Sildenafil (Revatio) was recently FDA approved for PAH. Although doses used clinically vary from 20 to 100 mg TID, at this time, only the 20 mg TID dose has received FDA approval. The longer acting tadalafil is currently under investigation for PAH, with once daily dosing. Bosentan lowers plasma sildenafil levels, 34 and dosage may need to be adjusted if these agents are used in combination. Side effects of sildenafil include headache, dizziness with hypotension, flushing, heartburn, blue-lavender vision, and, rarely, sustained erections. Patients should be cautioned to avoid nitrates, as coadministration can cause significant hypotension. If nitrates are required for concomitant coronary artery disease, sildenafil is contraindicated. Sildenafil may be used in the acute setting to aid weaning from NO. Once sildenafil is started, the NO is weaned down by 5 ppm until 5 ppm is reached, then down by 1 ppm until off to avoid rebound PH. 45 The third pathway and treatment target is the prostacyclin pathway. Prostacyclin analogs or prostanoids are available currently in intravenous, subcutaneous, and inhaled forms. There are pros and cons to each formulation, and the choice of a prostanoid is an individual decision made with the patient, family, and healthcare providers on the basis of the severity of the patient's disease, availability of home support, lifestyle considerations, and patient's preference. Side effects common to the prostanoids include headache, flushing, rash, nausea, diarrhea, and painful jaw spasm when taking the first bite of food. Side effects associated with long-term chronic use include blotchy-red rash, musculoskeletal pain, predominantly in the feet and legs, impotence, thrombocytopenia, ascites, and potential high-output cardiac failure with longterm overdose. 38 Epoprostenol (Flolan) was the first medication approved for IPAH in 1995. Thus, there is the most experience with this medication compared with all PAH therapies. Epoprostenol was also shown to improve PH due to scleroderma spectrum of disease, 46 or associated with congenital left-to-right shunts, portal hypertension, and HIV. 29 Long-term benefits of epoprostenol on survival, hemodynamics, exercise capacity, and functional class are often sustained over time. 35 Survival was significantly improved for patients who achieved functional class I or II compared with those who remained functional class III and class IV after 12 weeks of treatment with epoprostenol. 47 Sitbon et al 48 found factors associated with poorer survival on epoprostenol were persistence of right heart failure, remaining functional class III or IV, and failure to achieve a decline in PVR of 30% or higher. Baseline variables (before starting epoprostenol) associated with poor outcome were the presence of right heart failure, functional class IV, 6-minute walk of 250 m or less, RAP of 12 or higher, and, paradoxically, mean PAP of 65 mm Hg or lower.
Epoprostenol has a 3-minute half-life, necessitating intravenous administration. It is usually given by CADD pump via a long-term tunneled central catheter, although peripherally inserted central catheters are used tem- porarily during episodes of central catheter infection (Fig 2) . Epoprostenol may be given via a peripheral line in emergency situations. Sudden discontinuation of epoprostenol can cause rebound PH, so patients are instructed in the management of emergency situations during their initial training. This includes having a backup pump, backup medication, contacting local emergency medical personnel and hospital emergency departments in advance, and carrying medical information with them at all times. Patients who have a sudden discontinuation of their epoprostenol due to a catheter problem require immediate peripheral line access with direct connection of their pump line to the hub of the catheter. Pump rates typically range from 26 to 96 mL per 24 hours, meaning that connection of the pump to an extension set could result in a significant delay in medication reaching the patient. Epoprostenol cannot be given with any other intravenous fluid or medication; it must run alone in a dedicated line. Patients reconstitute the powdered medication daily with a specific buffered diluent solution. The mixed medication is stable at room temperature for 8 hours, and 48 hours chilled. During the infusion, the pump is carried in a special insulated pouch, with frozen gel packs on either side of the medication cassette. These ice packs must be changed every 4 to 6 hours, depending on the ambient temperature. Patients often mix a dose ahead so that one dose is ready in the refrigerator at all times in case of emergencies. When it is time to change cassettes, the patient puts the cassette from the refrigerator on the pump, and then mixes a dose to be placed in the refrigerator. When epoprostenol is given in the hospital on standard infusion pumps, the daily dose can be divided into 8-hour aliquots to be hung at the appropriate intervals so that potency is assured with minimal wasting of drug.
In response to the complexities and obvious drawbacks of epoprostenol, other prostanoids have been developed. Treprostinil (Remodulin), originally developed as a subcutaneous form, is now approved for intravenous use and is under study in inhaled and oral forms. In contrast to epoprostenol, treprostinil has a 3-hour half-life and is stable at room temperature. 38 It is available in liquid form in various strength multidose vials to be drawn up directly for subcutaneous use or added to cassettes for intravenous use. Subcutaneous administration is via Minimed 407C pumps with various infusion sets, depending on patient preference and tolerance (Fig 3) . The infusion catheter is placed by the patient in a subcutaneous fat pad. The most commonly used site is the abdomen, but outer hips, thighs, and upper arm may also be used. The major limiting side effect of subcutaneous treprostinil is pain at the infusion site. The medication causes irritation, inflammation, redness, swelling, and pain at the infusion site (Fig 4) . There is a great range in site reaction, from minor redness and discomfort to severe pain requiring discontinuation of the drug. Centers expe- rienced in subcutaneous treprostinil have developed site pain management protocols, with treatments ranging from guided imagery to topical over-the-counter and prescription formulations to oral narcotics. PAH coordinators have been unable to predict which patients will have significant site pain and who will benefit from which pain treatment. Patients and their families are counseled about this side effect when therapy choices are given, and once subcutaneous infusions are begun, close contact with the PAH center, specialty pharmacy/distributor, and other patients is essential for success of this therapy. Typically, site pain is worst on the second and third days a site is used, and then decreases significantly. Patients change their infusion sites as directed by their PAH center. Centers vary from strict every 3-day changes to weeks. Although site abscess can occur, it is not common, even with prolonged site use.
In response to the infusion site pain associated with subcutaneous administration, intravenous administration of treprostinil was FDA approved in 2004. Long-term safety and efficacy (improvements in 6-minute walk distance, functional class, and hemodynamics) was shown in a 12-week prospective, openlabel, uncontrolled multicenter study in 16 patients with IPAH, and PAH associated with congenital heart disease, or connective tissue disease. Side effects were mild and similar to epoprostenol. 49 Transition from intravenous epoprostenol to intravenous treprostinil is safe and effective in stable patients. 50 Like epoprostenol, it requires a long-term central catheter and infusion pump. Since it is stable at room temperature, it does not require ice packs or frequent mixing. It is also possible to use miniature pumps for concentrated solutions (Figs 5 and 6 ). These smaller pumps are ideal for young, active patients, or those unable to carry heavier pumps (elderly or toddlers). The medication is mixed in a syringe with saline and attached or loaded into the pump. Pumping rates are very low with these miniature pumps, and anticoagulation may be needed to prevent catheter occlusion.
Inadvertent boluses of medication can be dangerous and must be guarded against.
Patients on intravenous prostanoid therapy should never have their catheters used for routine blood draws. Careful handing of the pump and programming is essential. These medications and pumps are distributed by specialty pharmacies whose 24-hour contact numbers are affixed to the pump in case healthcare providers unfamiliar with these devices or medications need assistance and the patient or family is unable to manage their therapy. Changing to a hospital pump should not be the first choice, as errors in concentration and dosage and delay in starting or inadvertent bolusing of prostanoid may occur. The specialty pharmacy can also facilitate communication with the treating PAH center if the patient presents to an outlying facility.
Epoprostenol and treprostinil are initiated at low doses (about 2 ng/kg per minute) and titrated up according to effect and patient tolerance. Patients with severe PAH and class III to class IV symptoms will be titrated more aggressively (2-4 ng/kg per minute each week). Uptitration is limited because of prostanoid side effects. These side effects occur with each increase in dose and usually last for about 24 to 36 hours. Some patients have severe side effects, whereas others have minimal side effects. Most side effects are managed with loperamide (up to 16 mg/d), an antiemetic and nonnarcotic analgesic. Rarely, hydrocodone or oxycodone with acetaminophen is required for severe headache or leg/body pain. The optimal dose of prostanoid is reached when the patient has relief from PAH symptoms, meets the treatment goals outlined above, and has minimal side effects. Typically after 1 year of therapy, patients are on about 20 to 30 ng/kg per minute of epoprostenol, 29 or the corresponding treprostinil dose of 35 to 60 ng/kg per minute (1.5-2 times epoprostenol dose).
The newest FDA-approved prostanoid is inhaled iloprost (Ventavis). Olschewski et al 51 reported that iloprost improved exercise capacity, functional class, and prevented clinical deterioration in PAH. Because the drug is delivered directly to the lungs, there are limited systemic side effects. One unique side effect of inhaled iloprost compared with the other prostanoids is cough. This may be mitigated by lozenges taken before the treatment and rinsing the mouth or gargling after the treatment. The serum half-life of iloprost is about 20 minutes. Six to 9 treatments per day while awake are recommended. Treatment is initiated at 2.5 μg, then 5 μg, and thereafter unless the patient requires down titration for excessive side effects. 52 The medication is given with a specific ultrasonic nebulizer (Fig 7) , using vibrating titanium mesh technology to achieve a particle size of less than 5 μm to ensure alveolar deposition. Pulsed medication delivery only during the first part of inhalation minimizes exhalation of drug. 53 The device cannot be sterilized and is single-patient use. Patients on supplemental oxygen should use a nasal cannula, and oxygen-conserving devices must be switched to "continuous," as the patient's inhalation will not be detected during the treatment since inhalation occurs through the nebulizer. Patients must be trained in appropriate breathing patterns to maximize drug delivery and shorten treatment times. The optimal breathing pattern is slow, deep breaths, with no hold on inspiration. Treatment times should be about 8 to 12 minutes. The device requires very specific and careful cleaning and rinsing with distilled water (or sterile water in hospital) after each use. Hard water can cause calcium deposits, which clog the microscopic pores of the mesh and prolong treatment times. The mouthpiece and medication chamber should be boiled in distilled water weekly. 53 Patients on iloprost who are admitted to hospital should continue their treatments with their own nebulizers as long as they are able to do so. In the event that intubation is required, transition to an intravenous prostanoid may be needed. Once the patient is stabilized and extubated, he or she may be transitioned back to iloprost.
Inhaled iloprost may be the prostanoid of choice for patients unwilling to have intravenous catheters or who feel they cannot tolerate possible site pain from subcutaneous infusion. The inhalation route offers benefits in terms of systemic side effects and in patients with ventilation-perfusion mismatch. 35 At this time, the only way to increase the iloprost dosage is to increase the frequency of treatments up to every 2 hours. Studies are under way to evaluate the efficacy of longer treatment intervals (4 treatments per day) in conjunction with oral PAH medications.
The discovery of multiple pathways and disease mechanisms for PAH make combination therapy using multiple treatment targets theoretically possible and clinically attractive. Theoretically, attacking the disease from multiple pathways makes sense and may result in lower doses of each drug, yielding fewer overall side effects. 38 The safety of various combination therapies (epoprostenol and bosentan, bosentan and sildenafil, and iloprost and sildenafil) has been studied or reported. 54 Several efficacy studies of combination therapy are in process. In clinical practice, however, combination therapy using all treatment pathways is prescribed. It remains to be seen which combinations are most efficacious for which subgroups of patients. It is also unknown whether drugs should be started in stepwise fashion or whether multiple pathways should be targeted from the start of treatment.
Lung transplantation remains the only "cure" for PAH and is reserved for patients failing medical therapy. Usually, double-lung transplantation is performed, although some centers may perform single-lung transplant. Heart-lung transplantation is required for patients with complex congenital heart defects (Eisenmenger's syndrome) that cannot be repaired at the time of lung transplantation. 55 In the past, priority for donor lungs for transplant was determined primarily by waiting time. Wait times could be 2 to 3 years for PAH patients, so many PAH centers sent patients for transplant evaluation at the time of diagnosis. In May 2005, new UNOS guidelines for lung transplant were enacted. Medical information is used to estimate severity of illness and chance of successful transplant, yielding a Lung Allocation Score (LAS). The LAS is updated at least every 6 months and as needed according to change in patient condition. Compatible candidates with the highest LAS will receive the lung offer. 56 Patients and their PAH healthcare providers may have difficulty determining the appropriate time for transplant listing. The ideal time to transplant is when the patient's predicted survival on medical therapy is less than that with a transplant, and the patient has sufficient reserve to tolerate the procedure. 55 Patients often do well on therapy but may deteriorate suddenly. The "window" of time available for transplant with a good outcome seems very short and difficult to determine. Although patients often say they are doing "fine," their family members report more and more selflimitation of activities. Assessment of exercise capacity by cardiopulmonary exercise testing may be helpful to quantify patients' functional limitation, determine prognosis, and priority for transplant. 57, 58 Patients who have a poor response measured by functional class to maximal therapy should be referred for transplant evaluation.
The psychosocial toll of PAH on patients and their families is immense. Physical and emotional health-related quality of life is severely impaired in patients with PAH, correlated with functional measures and unrelated to hemodynamics or type of vasodilator therapy. 59 Our patients are predominantly young, childbearing age women who must be told that they have an incurable disease and counseled against any future pregnancy. The treatment options are complex and require major lifestyle modifications and body image impact. Many patients have struggled with symptoms for years before diagnosis. PAH therapies are extremely expensive, creating sometimes insurmountable insurance problems. Currently, bosentan is in the range of $36,000 per year; sildenafil $12,000 and prostanoids $70,000 to $150,000 depending on type and dose. The costs of bringing a PAH drug to market must be recouped from hundreds of thousands of future patients rather than millions, as with other drugs for more common conditions. Young, previously healthy patients choose health plans with minimal prescription benefits or high deductibles that now preclude lifesaving therapies. Many patients are working with no healthcare benefits from their employers. Their working salary eliminates them from Medicaid and they cannot afford to buy high-risk pool insurance. Unfortunately, insurance dictates therapy choices and the frequency of diagnostic tests to monitor treatment response in many cases. Participating in a research study is the only alternative for some who meet the sponsor's entry criteria. PAH coordinators spend long hours obtaining prior authorizations and processing appeals for denial of treatment. As public and medical community awareness of PAH improves, this process should be easier, as the public demands treatment for PAH that is in line with other chronic, incurable diseases.
Nurses are instrumental in patient/family education for PAH. ("Family" includes all persons the patient considers significant in their life.) Patients and families are taught about the disease process and all the available and appropriate treatment options. Depending on the identified etiology, patients or their parents, especially, may experience guilt over past behavior or not being aggressive in demanding treatment. The time of diagnosis is very stressful and overwhelming for the patient and family. Feelings of loss and fears for the future lead to a normal grieving process. By educating the patient and family about treatment options, dispelling misinformation about prognosis, and supporting effective coping mechanisms, the nurse helps the patient and family deal with this difficult diagnosis and treatment decision. PAH nurses lead patient support groups where information can be shared between patients and families, education is provided, and group support is facilitated. The Pulmonary Hypertension Association sponsors many support groups as well as maintains an excellent educational Web site for patients and healthcare providers and a biannual international conference designed for both patients and professionals. (See Table 5 for selected Internet resources.)
At the time of diagnosis, all therapies and treatment options including research protocols are discussed with the patient and family. The patient and their family must be involved in treatment decisions because compliance is essential and there are financial and lifestyle implications to treatment choices. The pros and cons of each treatment option are explored (Table 6 ). Most patients opt for oral therapy before taking prostanoids because of their complexity. The exception is patients with class IV symptoms who may require hospitalization for stabilization and likely will need intravenous therapy.
Once a treatment decision has been made, the nurse teaches the patient and the caregiver about the management of the therapy including expected medication effects, side effects, pump or device use, catheter care, and what to do in an emergency. PAH centers are supported by nurses and staff from the specialty pharmacies that distribute PAH medications. Teaching by the PAH center is reinforced at home by the specialty pharmacy nurses, and in some cases, therapy may be initiated at the patient's home. Patients are contacted on a regular basis for reordering of medication and supplies, and this contact is used by the specialty pharmacies to evaluate response to treatment, compliance, and to elicit any problems with the therapy that they can relay to the PAH center.
Symptom management is another area where nurses can educate patients to facilitate some control over their illness. PAH symptoms, as mentioned above, are treated with uptitration of prostanoids or additional PAH medications. Symptoms of right heart failure are treated with more diuretics and attention to sodium and fluid control. Side effects of medications include heartburn, thirst, chronic pain from subcutaneous infusions or neuropathic pain, muscle pain associated with hypokalemia, diarrhea, and nausea. Patients often complain of insomnia, and depression is common. Patients need information on why these symptoms occur, how they can avoid them, and potential remedies, both over-the-counter and prescription formulations. It has been said that PAH patients' fate is determined by their right ventricle. Regardless of the PAP, the ability of the right heart to pump against this pressure and fill the left ventricle is crucial. Avoidance of right heart failure is a survival skill for these patients. In addition to maintaining compliance with their PAH therapies, patients need to manage their sodium and fluid balance. Patients weigh themselves daily, notifying their center, or adjusting their diuretics for weight gain of 2 lb/d or 5 lb/wk. Patients may be instructed to restrict their sodium intake (2-3 gm/d depending on the center) and their fluid intake (typically 1.5 L/d). Compliance with diuretics and potassium supplements is important, as patients may be on loop diuretics, thiazides, and aldosterone antagonists. Electrolytes are checked when diuretics or potassium supplements are changed, and these medications are carefully balanced; particularly, if low-dose digoxin (0.125 mg daily) is used, serum potassium level should be maintained at 4.0 mg/dL.
Patients are followed closely by the PAH center for monitoring of deterioration and need for additional therapy or referral for transplant. The frequency of clinic visits will depend on the patient's proximity to the center and stability, usually every 3 to 6 months. Assistance from a primary care provider for routine medical care, treatment of long-term catheter complications, monitoring laboratory results, and adjusting potassium and warfarin doses is essential, especially for patients living far away from the center or those enrolled in health maintenance organizations. Six-minute walk tests are performed routinely at clinic visits in conjunction with functional class assessment and vigilance for right heart failure symptoms. Echocardiograms are routinely obtained every 6 to 12 months. Some PAH centers routinely repeat RHCs at prescribed intervals, but most perform only RHC if the patient is deteriorating or not responding adequately to therapy. Living with PAH requires many adjustments and adaptations from the patient and the family. In addition to modifications in diet for sodium and fluid restrictions, most patients need to make modifications in terms of energy intake. Most PAH patients are overweight, some morbidly obese. These patients have difficulty losing weight because of their inability to exercise and limited physical ability to shop and cook. Many convenience foods have high calorie as well as high salt content. A few patients, especially those who have been on chronic prostanoid therapy, experience severe weight loss over time. This is related to side effects (jaw pain, nausea, and diarrhea), fatigue, and shortness of breath, which make eating an effort. These patients are encouraged to think of food as another medicine, to eat small, frequent meals (3 meals and 3 snacks per day), using pudding or liquid nutritional supplements.
New tasks and limitations to integrate into their daily life include multiple oral medications to remember, including diuretics and warfarin, which complicate diet and can limit freedom of movement. Multiple laboratory draws are needed to follow electrolytes, LFTs, or prothrombin time/INR for warfarin. Patients may need to adjust to chronic oxygen therapy, not only managing tanks or portable liquid devices but also coming to terms with a change in body image. Living with a pump or a central catheter if on intravenous therapy is an adjustment; remembering the pump is in your pocket, or holding on to it when you get up from a chair or exit a car. Living with chronic site pain or musculoskeletal pain from prostanoids requires emotional, psychosocial, and pharmacologic interventions. Multiple issues surrounding sexual functioning arise.
Birth control for women is mandatory, as pregnancy can be life-threatening to both mother and baby. Since pregnancy is contraindicated and the effects of medications on ova are unknown, women may want to pursue egg harvesting or donation and surrogate pregnancy as options. Body image and intimacy issues related to the pump, catheter, or infusion site, and disease symptoms can make sexual intimacy and intercourse challenging for patients and their partners. If symptoms, particularly syncope, have occurred during intercourse, patients and/or their partners may be fearful of sexual contact and need explicit discussions and guidance from their PAH healthcare providers. Finally, once the patient has adjusted to their therapy, they should be encouraged to resume leisure activities and vacations as before their diagnosis. Traveling with PAH requires some advance planning (arranging medications and oxygen), but it is still possible and very rewarding for the patient and family to feel some degree of return to normalcy.
Energy conservation techniques are necessary for the patient to be able to complete their activities of daily living. Severely ill, class IV patients may benefit from physical and occupational therapy during hospitalization, with continued outpatient home therapy. As they get stronger, outpatient cardiopulmonary rehabilitation should be considered to optimize physical conditioning.
Depression is common in chronic disease, and PAH is no exception. Many patients benefit from antidepressant medications; others prefer participating in support groups or online chat rooms or professional counseling. Patients who report increasing fatigue, sleepiness, and loss of appetite should be screened for depression.
At some point, all PAH patients and their families should be counseled regarding endof-life decisions and care. These discussions, though difficult, are best begun early in the patient-provider relationship when there is adequate time for discussion and decision making. Patients should be encouraged to draft an "advance directive," to name a surro-gate decision maker in a "durable power of attorney for healthcare," or to specify their wishes in a "living will"type document. When end of life is at hand, hopefully the patient has thought about and discussed his or her preferences with the healthcare providers and family. Palliative care can be provided at home or in hospital. Financial issues and insurance coverage can complicate hospice or skilled nursing facility placement. The insurance per diem payment is not adequate to cover the cost of PAH therapies, and sudden withdrawal of therapy can cause severe shortness of breath and distressing symptoms at end of life. This issue will become more prevalent as PAH patients live longer, particularly patients with PAH associated with collagen vascular disease who tend to be older than IPAH patients. Elderly patients who have been on pump therapies for years may at some point be unable to manage their therapy and may not have family to provide 24hour care. Currently, it is virtually impossible to get insurance coverage for skilled nursing facility placement for these types of patients. Whether PAH patients die in hospital or at home, they and their families need a great deal of support through the process of death. Optimally, the patient's wishes regarding resuscitation, intubation, and extraordinary treatment measures are known and documented. Intravenous analgesia and anxiolytics can manage symptoms of chest pain and dyspnea, while maintaining some degree of consciousness according to the patient's wishes.
Although still classified as a rare disease, the incidence of PAH seems to be increasing. Critical care nurses may encounter these patients as admissions through the emergency department or perioperatively. Rapid progress in PAH therapy and disease understanding will continue, as more therapies are approved and more insight is gained into the mechanisms of PAH. Nurses are an essential component of the PAH team to assist patients and their families with understanding the disease, managing the treatment, and adapting to a life with PAH.
CASE STUDY (SIDEBAR)
In 1995, at the age of 30, Mary (not her real name) starting having symptoms of shortness of breath after walking about 25 ft, syncope, peripheral edema, and fatigue. Two years later, she was diagnosed by a local cardiologist with primary PH with pressures of more than 100 mm Hg, and treated with benazepril, warfarin, digoxin, and diuretics. Mary was referred to the PH service in the fall of 1999 after 2 years of NYHA class III symptoms and progressive peripheral edema. Mary denied use of amphetamines or fen-phen, exposure to HIV, and collagen vascular disease diagnosis or symptoms. Her V/Q and computed tomographic scans were negative for thromboembolic and interstitial lung disease. Her 6-minute walk was 283 m, BORG 3/10. All treatment options were discussed with the patient including epoprostenol, research medication, and lung transplantation.
On November 5, 1999, the patient started subcutaneous UT-15 (treprostinil) as a double-blind placebo controlled trial. At the end of the trial, RHC on January 27, 2000, demonstrated PAP 128/48, mean 76, PCWP 11, and cardiac output 4.1 L/min. Mary then entered the open-label extension trial of UT-15. She gradually increased her dose of treprostinil, with dramatic improvement in symptoms. On September 19, 2001 , echo demonstrated RVSP 84, dilated and hypertrophied RV with no pericardial effusion, and estimated cardiac output of 4.8 L/min. Mary returned to the center for study visits, but was followed primarily by her local cardiologist. In 2003, the open-label study ended, the drug became commercially available, and Mary needed strong encouragement to make her rare appointment at the PH clinic. On March 29, 2004 , the dose of treprostinil was 80 ng/kg per minute.
Mary returned to the clinic on November 29, 2004. Her 6-minute walk was 371 m. She reported site pain, especially on days 2 and 3 of the infusion, but stated it was not intolerable. An echo on December 10, 2004, demonstrated RVSP 102, dilated and hypertrophied RV with a small pericardial effusion.
Mary's next clinic visit was not until March 24, 2006. She presented with complaints of intolerable both infusion site pain and prostacyclin side effects. An echo had been obtained by her local cardiologist demonstrating RVSP 112, with mild-moderately enlarged right ventri-cle and right atrium and questionable small pericardial effusion. Her 6-minute walk that day was 408 m. Because of the severe site pain, Mary was changing sites very frequently, sometimes more than once a day, and leaving the catheter out for 8 hours (probably more), particularly at night. The pump was set to deliver 80 ng/kg per minute, so the patient was effectively bolusing herself with medication, then taking the infusion off until her PH symptoms forced her to restart the infusion. Physical examination demonstrated normal jugular venous pressure, RV lift, murmurs of pulmonic insufficiency and tricuspid regurgitation, very loud P 2 , and no peripheral edema. After much discussion and education on the PAH medications now available, the patient agreed to restart her infusion at 40 ng/kg per minute (half the dose) and try to leave it continuously. Sildenafil 50 mg TID was started, and she was instructed to increase to 100 mg TID after 3 days if tolerable. After several days on the higher dose of sildenafil, Mary began slowly lowering the treprostinil dose. Telephone follow-up was conducted over the next 6 weeks to ensure compliance and support the patient through the site pain and change in therapy. Mary reported no PH symptoms and good activity tolerance, but still significant site pain, even with lower doses of treprostinil.
Early in June 2006, Mary called with increased peripheral edema and 10-lb weight gain. Metalozone 5 mg half an hour prior to her morning furosemide dose was added 2 to 3 times per week. This immediately decreased her weight and edema, and on June 7, 2006, she had no edema with a 6-minute walk of 442 m. Mary's treprostinil dose was now 24.3 ng/kg per minute, but she was still taking it out at night to sleep. She was also noticing more PH symptoms at this lower dose. It became clear to the patient, as we had expected, that she would not be able to wean off prostanoid therapy. Approval for inhaled iloprost was obtained.
On the morning of July 10, 2006, Mary came to the clinic for transition from treprostinil to iloprost. Although she brought all of her treprostinil supplies with her, the infusion had been off since 10:00 PM the night before. The nurse from the specialty pharmacy brought the iloprost and supplies and trained the patient and family on the therapy. Mary took the first 2.5 μg treatment without incident. Her 6-minute walk was 363 m, BORG 3/10. Physical examination revealed normal jugular venous pressure, no peripheral edema, and increased P 2 with RV lift. After a 2-hour break, the patient returned for the second, 5 μg treatment. She needed significant coaching with breathing technique to take long, slow, deep breaths. Her treatment times were long at 15 minutes. Mary tolerated the inhalations with no side effects and had stable vital signs. She denied dizziness, cough, headache, or jaw pain. Mary was instructed to return to clinic in 1 month.
A telephone follow-up interview in the first week of iloprost therapy found Mary very satisfied with the therapy. She reported taking 5 to 6 treatments per day, with minimal side effects. She was very happy to be relieved of infusion site pain and stated her abdomen was starting to heal up nicely. Mary admitted that the frequency of treatments and the cleaning ritual was "a pain," but was willing to put up with it so as not to have chronic pain. She also reported much improved sleep without treprostinil. We discussed the addition of an ERA (bosentan or sitaxsentan) if the combination of iloprost and sildenafil is not adequate in terms of symptom control and maintaining functional status. At the next scheduled clinic visit, another 6minute walk would be performed and additional medication would be considered.
